Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) advanced an analytical method — refractive index detection with gel permeation chromatography (RI-GPC) — to characterize a key polymer in its PNKP Inhibitor Technology. The polymer forms the nanoparticle micelle delivery system for lead candidate ONC010. The qualification aims to improve polymer molecular-weight control, support formulation reproducibility, enable manufacturing scale-up, and strengthen the CMC package ahead of IND-enabling studies and planned Phase 1 activities.
Onco-Innovations (OTCQB:ONNVF) announced completion of analytical method development for its monomer intermediate supporting ONC010. A robust RP-HPLC method was developed and pre-validated with high sensitivity, linearity, and consistent chromatographic behavior to support impurity detection, quality control and future GMP activities.
Process development yielded intermediary scale batches of ~20 g and ~181 g, each confirmed at not less than 98% purity by HPLC; the method will form the basis for formal CMC analytical procedures as the company advances toward IND-enabling work.
Onco-Innovations (OTCQB:ONNVF) appointed Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development effective April 17, 2026. The hires aim to advance the company's PNKP Inhibitor Technology (ONC010) through IND-enabling activities toward first-in-human studies and improve regulatory and CMC readiness.
The board also approved issuance of 1,360,000 RSUs, and the company's preliminary base shelf prospectus remains under review by the Alberta Securities Commission.
Onco-Innovations (OTCQB:ONNVF) executed an engagement agreement with RDI Partners and formed Onco-Innovations AU Pty. Ltd. to support planned Phase I development in Australia. The company also engaged MCS for digital marketing services and paid EUR 213,000 for services through July 30, 2026.
The initiatives aim to position potential eligibility for Australia’s 43.5% R&D Tax Incentive, prepare HREC submission, follow TGA CTN pathway, and strengthen governance and financial oversight for clinical activation.
Onco-Innovations (OTCQB:ONNVF) closed a non-brokered private placement on March 12, 2026, issuing 1,870,000 units at $0.65 per unit for aggregate gross proceeds of $1,215,500.
Each unit included one common share and one three-year warrant exercisable at $0.75 through March 12, 2029. The company issued 18,700 administrative shares and will use proceeds for general corporate and working capital purposes.
Onco-Innovations (OTCQB:ONNVF) amended pricing for a non‑brokered private placement dated February 12, 2026. The company intends to issue up to 3,076,923 Units at $0.65 per Unit for gross proceeds up to $2,000,000.
Each Unit includes one common share and one warrant exercisable at $0.75 for three years. The company will issue Admin Fee Shares equal to 1.0% of placement Shares, may pay finders' fees or issue finders' warrants, and will use proceeds for general corporate, R&D and investor relations. Closing is subject to regulatory approvals; securities carry a four‑month plus one‑day hold.
Onco-Innovations (OTCQB:ONNVF) filed a preliminary base shelf prospectus dated February 3, 2026 with Canadian provincial securities regulators. The filing is preliminary and not final; securities may not be sold until a final receipt and prospectus supplement are obtained.
The shelf, if finalized, would permit the company to offer common shares, debt securities, warrants, subscription receipts and units over a 25-month effective period to provide financial flexibility. Securities are not registered for sale in the United States and may not be offered there absent registration or an exemption. A copy is available on SEDAR+ under the company profile.
Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 2,272,727 Units at $0.88 per Unit to raise gross proceeds of up to $2,000,000. Each Unit includes one common share and one-half warrant, with each whole warrant exercisable to buy one share at $1.10 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of Shares issued in the placement to an arm's-length third party and may pay finders' fees or issue finders' warrants on warrant terms. Closing is subject to regulatory approvals; securities will carry a four-month-plus-one-day hold. Proceeds are intended for general corporate, working capital, R&D and investor relations purposes. Securities are not registered for sale in the United States.
Onco-Innovations (OTCQB:ONNVF) engaged i2i Marketing Group LLC to provide market awareness and corporate communications services, including content creation, project management, third-party media distribution, and digital market awareness initiatives.
The initial budget for the i2i program is USD $400,000, scheduled to run until July 14, 2026 or until the budget is exhausted, with ongoing evaluation and optimization. The company also obtained a return of the remaining unused balance of €213,000 from a prior market awareness provider. The company disclosed that i2i holds no direct or indirect interest in its securities.
Onco-Innovations (OTCQB:ONNVF) chaired Colorectal Cancer Canada’s fourth Catalysts roundtable, Beyond Borders: Data-Driven Innovation for Global Precision Oncology, held virtually on December 2, 2025. The invitation-only session gathered ~20 senior leaders from industry, government, academic medicine, and clinical programs to discuss national scalability, data governance, interoperability, and transportable evidence for precision oncology.
Speakers included leaders from BC Cancer, University of Calgary, Inka Health, and others. Next steps: an internal roundtable report, a 2026 manuscript integrating series insights, advocacy materials on data innovation, and formation of working groups to advance AI-enabled precision medicine.